Cyanotech receives Nasdaq non-compliance notice

Cyanotech Corporation (Nasdaq Capital Market: CYAN) has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010. Mr. Rosenthal has resigned from the audit committee in order to accept his interim appointment as an executive officer. Nasdaq rules require that the Board be comprised of a majority of independent directors and that the audit committee be comprised of only independent directors of which there must be at least three. The notification indicated that so long as Cyanotech provides an acceptable plan within 45 days to regain a majority of independent directors to the Board and to add a third independent member to the audit committee, NASDAQ will consider granting Cyanotech an exception for up to 180 days from March 8, 2010. Cyanotech intends to provide a plan acceptable to Nasdaq within the required time period.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.